Valeo Financial Advisors’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Valeo Financial Advisors’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4	Closed	-$2.73K	–	729
2023 Q3	$2.73K	Hold	4	–	–	﹤0.01%	619
2023 Q2	$18.1K	Hold	4	–	–	﹤0.01%	585
2023 Q1	$10.5K	Hold	4	–	–	﹤0.01%	608
2022 Q4	$10.3K	Hold	4	–	–	﹤0.01%	535
2022 Q3	$15K	Hold	4	–	–	﹤0.01%	497
2022 Q2	$10K	Buy	+4	New	+$10.4K	﹤0.01%	504
2021 Q2	–	Sell	-1	Closed	-$15K	–	1920
2021 Q1	$15K	Buy	+1	New	+$11.7K	﹤0.01%	1263

Other funds holding SEEL

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Valeo Financial Advisors's SEEL Position: Q4 2023 in Review

Valeo Financial Advisors sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 4 shares — an estimated $2.73K sold.

Valeo Financial Advisors first reported a position in SEEL in Q1 2021 and held it in 7 quarters. The position peaked at $18.1K in Q2 2023. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

Valeo Financial Advisors reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Valeo Financial Advisors sold 4 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $2.73K.
Valeo Financial Advisors first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Valeo Financial Advisors's Seelos Therapeutics, Inc. Common Stock position peaked at $18.1K in Q2 2023.
32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Valeo Financial Advisors's 13F filing for Q4 2023, filed 29 Jan 2024.